ClinConnect ClinConnect Logo
Search / Trial NCT01775046

Valiant Thoracic Stent Graft With the Captivia Delivery System in the Treatment of Descending Thoracic Aortic Diseases (VALIANT CAPTIVIA France)

Launched by MEDTRONIC CARDIOVASCULAR · Jan 23, 2013

Trial Information

Current as of August 02, 2025

Completed

Keywords

Valiant Captivia Stent Graft Thoracic Aortic

ClinConnect Summary

Data regarding the use under routine practice of thoracic aortic stent grafts in France are expected by the French National Authority for Health (HAS). Therefore, in its opinion report from December 22, 2009, HAS makes the maintenance of reimbursement approval of each stent graft dependent on the presentation of results of a specific follow-up study carried out in a cohort of patients representative of the French population treated under real-life conditions of use. This prospective cohort study must involve patients implanted after registration on the LPPR (List of Products and Services qu...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Any patient requiring placement of the Valiant Thoracic Stent Graft for the treatment of a disease of his/her descending thoracic aorta.
  • Patient or holder of parental authority not opposed to the collection and release of the personal information required by the study.
  • Patient or holder of parental authority has consented for study participation and the Medtronic approved Data Release Form has been signed and personally dated by patient or holder of parental authority and by the investigator.
  • Exclusion Criteria:
  • Patient in whom clinical follow-up will not be possible i.e. patient not able to come back for follow-up visits (ex. patient living abroad).
  • Prior implantation of a thoracic stent graft.

About Medtronic Cardiovascular

Medtronic Cardiovascular is a leading global healthcare technology company dedicated to transforming patient care through innovative medical solutions. With a focus on cardiovascular health, Medtronic develops advanced devices and therapies that address a wide range of heart and vascular conditions. Committed to clinical excellence and patient outcomes, the company conducts rigorous clinical trials to evaluate the safety and efficacy of its products, ensuring they meet the highest regulatory standards. Medtronic Cardiovascular strives to enhance the quality of life for patients worldwide while advancing the field of cardiovascular medicine through research and development.

Locations

Toulouse, , France

Créteil, , France

Limoges, , France

Marseille, , France

Paris, , France

Toulouse, , France

Paris, , France

Marseille, , France

Saint Priest En Jarez, , France

Le Plessis Robinson, , France

Saint Martin D'hères, , France

Amiens, , France

Bordeaux, , France

La Tronche, , France

Le Chesnay, , France

Marseille, , France

Villeurbanne, , France

Patients applied

0 patients applied

Trial Officials

Hervé Rousseau, MD, PhD

Principal Investigator

CHU Rangueil, 1 Avenue Jean Poulhes, TSA 50 032, 31059 TOULOUSE Cedex 9, FRANCE

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials